My group and I are researching to develop new, better cancer drugs and predictive biomarkers for the development of aggressive cancers. Among other things, we use the CRISPR / Cas9 method.
I and my collegues investigate how transforming growth factor b (TGFb) and Wnt3a, which are growth factors, activate molecular mechanisms that prostate cancer and kidney cancer cells use to become aggressive and metastatic in both in vitro and in vivo models, as well as in clinical materials from patients.
We use advanced cell, molecular and tumor biological methods including CRISPR / Cas9 that enable us to ask specific scientific questions with high precision. Our long-term goal is to develop new and better cancer drugs that can prevent the ability of cancer cells to invade and metastasize, as well as predictive biomarkers for patients at risk of developing aggressive cancers. We are now investigating a potential new cancer drug that we have developed in collaboration with the SciLifeLab Drug Discovery Development platform.